Advancements In GLP-1 Agonist Therapies For Diabetes And Weight Management GLP-1 agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists mimic naturally occurring incretin hormones to slow gastric emptying, increase the feeling of fullness, promote insulin secretion, and inhibit the inappropriate release of glucagon
Hy vng vi nhng g m chng ti chia s c th gip bn hiu hn v c ch, cng nh thi gian c th nhn bit c hiu qu khi s dng vin ung sng da
A 2025 meta-analysis published in Endocrinology, Diabetes & Metabolism, pooling data from four studies with nearly 29,000 patients, confirmed a consistent advantage for tirzepatide, with an average additional weight reduction of 4.84 kg compared to semaglutide
Excipient sensitivity is another consideration
Liu, Y., Kubota, S., Iizuka, K